Jci_page_head_homepage_01 Jci_page_head_homepage_02
Carlo Colombo, Ottavia Porzio, Ming Liu, Ornella Massa, Mario Vasta, Silvana Salardi, Luciano Beccaria, Carla Monciotti, Sonia Toni, Oluf Pedersen, Torben Hansen, Luca Federici, Roberta Pesavento, Francesco Cadario, Giorgio Federici, Paolo Ghirri, Peter Arvan, Dario Iafusco, Fabrizio Barbetti
Published in Volume 118, Issue 6
J Clin Invest. 2008; 118(6):2148–2156 doi:10.1172/JCI33777
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 5
Viability of transfected INS-1E cells.

Shown is the viability of INS-1E cells at 48 and 96 h after transfection with WT human (pro)insulin, hAkita mutation, human familial hyper(pro)insulinemia mutation R65L, and human MDI mutations R65C, CA6Y, LB15YB16delinsH, LB6P, LB11P, and YA19X. Human (pro)insulin was detected by monoclonal antibody directed toward the human C-peptide and C terminus of the B-chain of the (pro)insulin molecule. Few (LB6P and LB11P) or no (hAkita, R65C, CA6Y, LB15YB16delinsH, and YA19X) INS-1E cells expressing MDI mutations were visible 96 h after transfection.